STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3974 by analyst upside · 2026-06-27
MRVI
Maravai LifeSciences Holdings, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
-8.4%
implied upside to consensus target
Current Price $6.22
Consensus Target $5.7
Bull Target $6.0
Bear Target $5.0
Analysts Covering 5
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
2
Hold
2
Sell
1
52-Week Low $1.99
52-Week High $6.29
YTD Return +82.9%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -66.9x
EPS (TTM) $-0.71
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $205M
Profit Margin -51.1%
52-WEEK RANGE
52-Week Low $1.99
52-Week High $6.29
Current Price $6.22
Bear Target $5.0
Bull Target $6.0
● Now $6.22 ● Target $5.7
TRADING DATA
Avg Volume 2.6M
YTD Return +82.9%
Analyst Count 5
Consensus Hold
Upside to Target -8.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Maravai LifeSciences Holdings, Inc. (MRVI) is currently trading at $6.22 with a Wall Street consensus price target of $5.7, which is 8.4% below the current price over the next 12 months. 5 analysts currently cover MRVI, with a consensus rating of Hold - 40% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $6.0, while the most cautious has a target of $5.0.

MRVI operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 82.9% year-to-date and is currently trading near the upper end of its 52-week range of $1.99 – $6.29.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MRVI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo — Reiterated
Overweight → Overweight 2026-05-08 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2025-12-15 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2025-08-12 Building track record
Craig-Hallum — Reiterated
Buy → Buy 2025-08-12 Building track record
Craig-Hallum — Reiterated
Buy → Buy 2025-05-13 Building track record
Baird — Reiterated
Neutral → Neutral 2025-05-13 Building track record
Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2025-03-25 Building track record
UBS — Reiterated
Neutral → Neutral 2025-03-21 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
14/30
Consensus clarity
27/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →